Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 10/20 | 0.49 |
| ▸ | TERT | O14746 | 1/20 | 0.48 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | FDPS | P14324 | 1/20 | 0.38 |
| ▸ | HTR6 | P50406 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL413787 | 0.88 | TAAR1 (0.50) | TAAR1TERTTBXAS1ALOX15HTR1A | |
| SCHEMBL12807438 | 0.87 | TAAR1 (0.49) | TAAR1TERTTBXAS1ALOX15HTR1A | |
| SCHEMBL9867040 | 0.86 | TBXAS1 (0.53) | TAAR1TERTTBXAS1ALOX15HTR1A | |
| SCHEMBL9866277 | 0.84 | TBXAS1 (0.56) | TAAR1TERTTBXAS1ALOX15HTR1A | |
| SCHEMBL1107199 | 0.83 | TAAR1 (0.46) | TAAR1TERTTBXAS1ALOX15HTR1A | |
| SCHEMBL12807569 | 0.82 | TAAR1 (0.53) | TAAR1TERTTBXAS1ALOX15HTR1A | |
| SCHEMBL285224 | 0.81 | TERT (0.59) | TAAR1TERTTBXAS1ALOX15HTR1A | |
| SCHEMBL590213 | 0.80 | — | — | |
| SCHEMBL23397872 | 0.79 | TAAR1 (0.50) | TAAR1TERTTBXAS1ALOX15HTR1A | |
| SCHEMBL28870215 | 0.79 | TAAR1 (0.47) | TAAR1TERTTBXAS1ALOX15HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107849024-A | With as indoleamine 2, the benzimidazole and imidazopyridine imido of 3 dioxygenase inhibitor activities are for benzamide compound | 吉利德科学公司 | 2018-03-27 | — | — | CN | disclosed |
| US-9434711-B2 | Sulfonamides as TRPM8 modulators | JANSSEN PHARMACEUTICA, N.V. (BE) | 2016-09-06 | — | — | US | disclosed |
| US-20140315899-A1 | SULFONAMIDES AS TRPM8 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2014-10-23 | — | — | US | disclosed |
| US-8809327-B2 | Sulfonamides as TRPM8 modulators | JANSSEN PHARMACEUTICA, NV (BE) | 2014-08-19 | — | — | US | disclosed |
| US-20130040983-A1 | RAF KINASE INHIBITORS | RUGA CORPORATION | 2013-02-14 | — | — | US | disclosed |
| US-20130040983-A1 | RAF KINASE INHIBITORS | RUGA CORPORATION | 2013-02-14 | — | — | US | disclosed |
| US-20130040983-A1 | RAF KINASE INHIBITORS | RUGA CORPORATION | 2013-02-14 | — | — | US | disclosed |
| US-20120190674-A1 | SULFONAMIDES AS TRPM8 MODULATORS | BRANUM SHAWN T (US) | 2012-07-26 | — | — | US | disclosed |
| US-8153682-B2 | Sulfonamides as TRPM8 modulators | JANSSEN PHARMACEUTICA, NV (BE) | 2012-04-10 | — | — | US | disclosed |
| WO-2011085269-A1 | RAF KINASE INHIBITORS | SELEXAGEN THERAPEUTICS, INC. (US) | 2011-07-14 | — | — | WO | disclosed |
| WO-2011085269-A1 | RAF KINASE INHIBITORS | SELEXAGEN THERAPEUTICS, INC. (US) | 2011-07-14 | — | — | WO | disclosed |
| US-20090264474-A1 | SULFONAMIDES AS TRPM8 MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-10-22 | — | — | US | disclosed |
| US-5011838-A | Antiallergens, antihistamines | DOMPE FARMACEUTICI S.P.A. (IT) | 1991-04-30 | — | — | US | disclosed |
| EP-0397615-A2 | Pharmacologically active 2-substituted 3-(2-ethoxyethyl) imidazo [4,5-b] pyridines and pharmaceutical compositions containing them | DOMPE' FARMACEUTICI S.p.A. (IT) | 1990-11-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130040983-A1 | RAF KINASE INHIBITORS | BRAF, RAF1, ARAF | TAAR1 4072/4885TERT 1085/4885TBXAS1 638/4885 |
| US-20120190674-A1 | SULFONAMIDES AS TRPM8 MODULATORS | TRPM8, TRPM5, TRPM2 | TAAR1 610/4885TERT 4756/4885TBXAS1 399/4885 |
| US-20140315899-A1 | SULFONAMIDES AS TRPM8 MODULATORS | TRPM8, TRPM5, TRPM2 | TAAR1 610/4885TERT 4756/4885TBXAS1 399/4885 |
| US-20090264474-A1 | SULFONAMIDES AS TRPM8 MODULATORS | TRPM8, TRPM5, TRPM2 | TAAR1 610/4885TERT 4756/4885TBXAS1 399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.